Korro Bio, Inc. - KRRO Income before deduction of interest, taxes and amortization
The scalability of the Korro Bio, Inc. (KRRO) business model is based on a unified IT drug programming system that enables the monetization of licenses. The company's total operating profit reflects efficiency trends, where the 0.00 metric determines this level. Growth potential relies on preparations for the first therapy tests for alpha-1 antitrypsin deficiency and future sales of genetic error correction methods.
Korro Bio - analytical breakdowns and key metrics (KRRO)
- market value and analyst target forecast:
- issuer market value details:
- book capitalization information:
- business debt structure and liquidity details:
Debt to Capital Korro Bio, Inc.|KRRO - Long-Term Debt to Equity Ratio|Ratio of Short-Term Indebtedness to Capital Korro Bio Inc.|KRRO - Company Aggregate Debts|Debts to Net Assets Korro Bio|KRRO - Company Long-Term Debt|Company Short-Term Indebtedness Korro Bio|Quick Liquidity Indicator korrobio.com
- net income and valuation multiples indicators:
KRRO - Net Income|Company Profit Forecast Korro Bio, Inc.|KRRO - Price to Earnings Ratio|Forward P/E Multiple Korro Bio Inc.|KRRO - Price/Earnings to Growth Ratio|Business Value to Operating Income Before Depreciation Korro Bio|KRRO - Profit before payment of interest, taxes and amortization|Earnings per share for the trailing year Korro Bio|KRRO - Earnings per share for the last twelve months|Earnings per share growth in annualized terms for the last twelve months korrobio.com|KRRO - Earnings growth in current year|Projected earnings per share growth rate for next year Korro Bio, Inc.
Summary company analytics:KRRO Korro Bio, Inc.
This indicator measures cash flow from operating activities before depreciation, allowing investors to assess the business's actual ability to generate cash regardless of accounting write-offs. For Korro Bio, Inc. (KRRO), current operating cash flow reflects the efficiency of laboratory and computing system utilization, confirming the absence of equipment downtime during the preparation of experimental drug batches.
Competitors of Korro Bio, Inc. (KRRO)
Tempus (TEM) - Profit before interest, taxes and amortization|QGEN: Operating profit before deduction of amortization|Income before deduction of interest, taxes and amortization IONS (ionispharma.com)|RGEN: Operating profit EBITDA|RNA (Avidity Biosciences Inc) - Profit before payment of interest, taxes and amortization|CRSP (CRISPR Therapeutics Corp) - Operating profit EBITDA|GeneDx Corp (WGS) - Operating income before deduction of amortization|Profit before payment of interest, taxes and amortization Ultragenyx Pharmaceutical (RARE)|BEAM - Profit before interest, taxes and amortization|Sarepta - Operating profit before deduction of amortization|Income before deduction of interest, taxes and amortization TWST|10x Genomics Corp - Operating profit EBITDA|Operating income before deduction of amortization Intellia Corp NTLA|Stoke Therapeutics (STOK) - Profit before payment of interest, taxes and amortization|Operating profit before amortization BLFS|WVE (Wave Life Sciences Ltd.) - Operating profit EBITDA|Operating profit before deduction of amortization Maze Therapeutics, Inc. (MAZE)|Operating profit before deduction of amortization SION (Sionna Pharma)|Operating income before deduction of amortization Prime Medicine Bio|Profit before payment of interest, taxes and amortization Taysha Gene Therapies TSHA|Operating profit EBITDA uniqure.com QURE|MGTX - Profit before payment of interest, taxes and amortization|Income before deduction of interest, taxes and amortization RGNX (REGENXBIO Inc)|Solid Bio (SLDB) - Profit before payment of interest, taxes and amortization|Ocugen Pharma - Income before deduction of interest, taxes and amortization|Profit before payment of interest, taxes and amortization Pacific Biosciences|Profit before interest, taxes and amortization benitec.com BNTC|Operating profit EBITDA DSGN|Rocket Pharma - Operating profit before amortization|Profit before payment of interest, taxes and amortization 4D Molecular Therapeutics Inc FDMT|LXEO: Operating profit before amortization|Editas Medicine, Inc. - Operating profit EBITDA|SLN - Operating profit EBITDA|proqr.com (PRQR) - Profit before payment of interest, taxes and amortization|Codexis (CDXS) - Operating profit EBITDA|Profit before payment of interest, taxes and amortization Sangamo|Profit before interest, taxes and amortization Nautilus Biotechnology Inc NAUT|Profit before payment of interest, taxes and amortization Metagenomi, Inc. (MGX)|DTIL (precisionbiosciences.com) - Income before deduction of interest, taxes and amortization|Profit before payment of interest, taxes and amortization Generation Bio GBIO|Income before deduction of interest, taxes and amortization BOLD|XCUR - Profit before payment of interest, taxes and amortization|Profit before interest, taxes and amortization Imunon, Inc.|PHIO (phiopharma.com) - Operating profit before deduction of amortization|Mustang Bio - Income before deduction of interest, taxes and amortization|RNAZ (TransCode Therapeutics Inc.) - Operating profit EBITDA|Profit before payment of interest, taxes and amortization BNGO|Operating profit EBITDA APDN|Operating income before deduction of amortization bluebird bio, Inc|Profit before payment of interest, taxes and amortization ImmunoPrecise Antibodies Ltd. IPA|omegatherapeutics.com (OMGA) - Profit before interest, taxes and amortization|OMIC: Operating profit before deduction of amortization|Income before deduction of interest, taxes and amortization RGLS (Regulus Therapeutics, Inc.)|SYRS: Operating profit EBITDA|TBIO - Operating income before deduction of amortization|Profit before payment of interest, taxes and amortization TRACON Pharmaceuticals|Operating profit before amortization UBX (unitybiotechnology.com)
